In a presentation titled “Biosimilar Medicine: Changing Landscape in Health Care,” given on Monday at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, J. Eugene Huffstutter MD, FACP, FACR, shared practical considerations for using biosimilars in the rheumatology clinic.
In a presentation titled “Biosimilar Medicine: Changing Landscape in Health Care,” given on Monday at the 2017 American College of Rheumatology Annual Meeting in San Diego, California, J. Eugene Huffstutter MD, FACP, FACR, shared practical considerations for using biosimilars in the rheumatology clinic.
Among the potential issues that a physician could encounter with a biosimilar in practice are the following:
However, Huffstutter pointed out that there are other risks associated with a transition to biosimilars, some of which are not discussed as often as the above:
Furthermore, rheumatologists have a steep learning curve ahead. Huffstutter called on rheumatologists to familiarize themselves with state laws governing substitution of interchangeable biosimilars, availability of patient support programs, insurance contracts, formulary status, and—critically—patient acceptance of biosimilars. Patients, he says, have “been left out of this whole discussion.”
But before biosimilars will achieve widespread adoption in rheumatology, the issue of cost must be addressed. Huffstutter shared many rheumatologists’ frustrations about the high cost of biologics, and was bemused by CMS’ wholesale acquisition cost that determines reimbursement for biosimilars. “[I] want CMS to tell us where they get these prices from so I can buy it from there, because it’s certainly a lot cheaper than what I can buy it for,” he said.
Instead of putting the onus for high costs on the drug manufacturers—“not only do we throw [manufacturers] under the bus, we back up and run over them again”—Huffstutter blamed PBMs, who profit from rebates provided by manufacturers in exchange for formulary placement, for potentially blocking biosimilar access. “That’s where the money is…[a manufacturer's profit] is chump change compared to what is going on [with PBMs],” said Huffstutter. “I don’t care how good a rheumatologist you are: if you can’t get a drug to a patient, you’re wasting your time.”
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.